Redefining the discovery and development of best-in-class oligonucleotide therapeutics
Our Mission
With OligoCreator, our AI-empowered drug discovery platform, we deliver on our mission to transform untreatable conditions into treatable ones, profoundly changing the future of medicine.
OligoCreator, our AI-empowered drug discovery platform, combines both innovative and proven delivery modalities with the precision and specificity of oligonucleotides.
Global partner of choice for oligonucleotide drug discovery and development programs.
About us
We redefine the discovery and development of best-in-class oligonucleotide therapeutics. With our AI-empowered OligoCreator platform, which integrates a variety of delivery technologies, we identify and characterize oligonucleotide therapeutics with unparalleled speed and excellent safety and efficacy. By precisely delivering these novel therapeutics to specific cells, organs or tissues, targeted oligonucleotide therapies have the potential to revolutionize treatments for a wide range of difficult-to-treat disorders. Our unique OligoCreator platform is leveraged to transform untreatable conditions into treatable ones, profoundly changing the future of medicine.
Latest News & Events
Secarna Announces Appointment of Konstantin Petropoulos as Chief Executive Officer
Martinsried (Munich), Germany, October 31, 2024 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the promotion of Konstantin Petropoulos, PhD, MBA, to Chief Executive Officer. He has served as the Company’s Chief Business Officer since June 2023. Alexander Gebauer, MD, PhD, is stepping down with immediate effect to focus his efforts on another company, Galimedix Therapeutics, that he has co-founded and is leading. He will continue to support Dr. Petropoulos in his new role to ensure a smooth transition.
Secarna Pharmaceuticals will present data at 6th Inflammasome Therapeutics Summit demonstrating the potential of ASOs to target the expression of NLRP3
- NLRP3 is a promising target with a well-validated role in various inflammatory disease
- Secarna has shown the potential of the company’s ASOs to effectively and specifically suppress NLRP3 and IL-1β release
- In a CAPS mouse model, Secarna demonstrated prolonged survival and a significant reduction in systemic inflammation
Secarna establishes Scientific Advisory Board with leading oncology experts Prof. Dr. Eggermont and Prof. Dr. Zippelius
- Scientific Advisory Board (SAB) to offer expert guidance and direction for the development of lead compound SECN-15 and the Company’s oncology pipeline
- Dr. Alexander M.M. Eggermont convened SAB as of July 1, 2024 together with Prof. Dr. Alfred Zippelius, who has been an advisor to Secarna since 2016
JP Morgan 43rd Annual Healthcare Conference 2025
18th Annual European Life Sciences CEO Forum (Sachs ELSF)
With our AI-empowered OligoCreator platform we streamline the identification and characterization of best-in-class oligonucleotide therapies to deliver transformative treatments and hope to patients in need by pushing the boundaries of medical science and transforming lives for the better.
Konstantin Petropoulos, Ph.D., MBA
CEO